Myriad Genetics Inc (MYGN)

Exchange
NASDAQ
Symbol
MYGN
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic Substances
Description
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Country
USA

Stock price

At close: October 4, 2024

  • Open
    26.77
  • High
    27.03
  • Low
    26.31
  • Close
    26.47
  • Volume
    441,430

Financial ratios

Jun 30, 2024

Activity ratios
Inventory turnover
25.98
Receivables turnover
6.75
Payables turnover
20.37
Working capital turnover
5.57
Days of inventory on hand (DOH)
14.05
Days of sales outstanding (DSO)
54.09
Number of days of payables
17.92
Fixed asset turnover
6.83
Total asset turnover
0.73
 Liquidity ratios
Current ratio
1.96
Quick ratio
1.44
Cash ratio
0.65
Cash conversion cycle
50.22
 Solvency ratios
Debt-to-assets ratio
0.04
Debt-to-capital ratio
0.05
Debt-to-equity ratio
0.05
Financial leverage ratio
1.47
Interest coverage
-47.97
 Profitability ratios
Gross profit margin
14.68%
Operating profit margin
-19.61%
Pretax margin
-19.70%
Net profit margin
-19.52%
Operating return on assets (Operating ROA)
-14.37%
Return on assets (ROA)
-14.30%
Return on total capital
-19.70%
Return on equity (ROE)
-20.96%